Psoriasis Treatment Market Research Report:
Information by Drug Class [Tumour Necrosis Factor Inhibitors (Adalimumab,
Infliximab and Etanercept), InterleU.K.in-Inhibitors (Ustekinumab,
SecU.K.inumab, Ixekizumab and Brodalumab), Vitamin D Analogues (Calcitriol,
Calcipotriol and Tacalcitol)], Treatment Type {Topicals [Over-the-counter (OTC)
Topicals, Topical Non-Steroids and Topical Steroids], Systemic (Retinoid,
Cyclosporine and Methotrexate), Biologics [Tumour Necrosis Factor Alpha (TNF-α)
Inhibitors, InterleU.K.in 12 and 23 (IL-12/23) Inhibitors, InterleU.K.in 17
(IL-17) Inhibitor, T cell Inhibitor]} and Region (Americas, Europe,
Asia-Pacific and Middle East & Africa) - Forecast till 2025
Market Analysis
The Psoriasis Treatment Market is
predicted to touch USD 13.1 billion at a 7.3% CAGR between 2019-2025, states
the latest Market Research Future (MRFR) report. Psoriasis, simply put, is an
autoimmune condition that causes rapid development of cells on the skin. The
overgrowth can result in scaly, thick plaques that may itch and cause
discomfort. Scales generally develop on joints, especially the knees and
elbows, but it may appear in any part of the body including the face, scalp,
neck, feet, and hands.
Various factors are propelling the global psoriasis treatment
market growth. Such factors, according to the latest Market Research Future
report, include vulnerability towards psoriatic arthritis, favorable
reimbursement policies, growing awareness about psoriasis, increasing
availability of biosimilars and biologics, aging population and changing
lifestyle. Additional factors propelling the growth of the psoriasis treatment
market include rising prevalence of autoimmune diseases, increasing incidence of
psoriasis, increasing R&D activities for psoriasis treatment, and
technological advancements.
On the contrary, lack of knowledge regarding the exact cause of
psoriasis and its etiology, the high price of medications with their low
efficacy and efficiency, side effects associated with symptomatic treatments,
and lack of permanent and effective treatment are factors that may hamper the
psoriasis treatment market growth during the forecast period.
Market Segmentation
The Market Research Future report offers a complete segmental
analysis of the psoriasis treatment market based on treatment type and drug
class.
By drug class, the psoriasis treatment market is segmented into
vitamin D analogues, InterleU.K.in-inhibitors, and tumor necrosis factor
inhibitors. The tumor necrosis factor inhibitors segment is again segmented
into etanercept, infliximab, and adalimumab. The InterleU.K.in-inhibitors
segment is again segmented into brodalumab, ixekizumab, SecU.K.inumab, and
ustekinumab. The vitamin D analogues segment is again segmented into
tacalcitol, calcipotriol, and calcitriol.
By treatment, the psoriasis treatment market is segmented into
biologics, systematic, and topicals. The topicals segment is again segmented
into topical steroids, topical non-steroids, and over the counter topicals. The
systematic segment is again segmented into methotrexate, cyclosporine, and
retinoid. The biologics segment is again segmented into T cell inhibitor,
InterleU.K.in 17 (IL-17) inhibitor, InterleU.K.in 12 and 23 (IL-12/23)
inhibitors, and tumor necrosis factor-alpha (TNF-a) inhibitors.
Browse Complete Report :https://www.marketresearchfuture.com/reports/psoriasis-treatment-market-2769
Regional Analysis
By region, the psoriasis treatment market report covers the
latest trends and growth opportunities across the Americas, Europe, the Asia
Pacific, the Middle East and Africa, and Latin America. Of these, North America
will spearhead the market during the forecast period. Various factors are
propelling the growth of the psoriasis treatment market in the region, such as
the growing awareness about psoriasis treatment, rising prevalence of
psoriasis, presence of key manufacturers, and increasing health
infrastructure.
The psoriasis treatment market in Europe will have the
second-largest share during the forecast period. Various factors are propelling
the growth of the psoriasis treatment market in the region such as growing
awareness about psoriasis, the launch of biosimilars (amzevita, elerzi), and
increasing prevalence of psoriasis.
The psoriasis treatment market in the APAC region will grow at
the fastest pace during the forecast period. Various factors are propelling the
growth of the psoriasis treatment market in the region such as growing
geriatric population, large patient pool, improving medical facilities and
healthcare infrastructure, increasing participation of key market players,
increasing investments to develop new therapeutics to treat psoriasis, and
increasing awareness.
The psoriasis treatment market in the MEA will have a small
share during the forecast period for the low economic development in
Africa.
The psoriasis treatment market in Latin America will have a
favorable growth during the forecast period owing to the focus of manufacturers
to create novel therapeutics and rise in the psoriasis patient pool.
Key Players
Notable players profiled in the psoriasis treatment market
report include Eli Lilly and Company (US), Amgen (US), AbbVie (US), Merck and
Co. Inc (US), Pfizer Inc (US), Johnson & Johnson (US), Celgene Corporation
(US), AstraZeneca (UK), UCB (Belgium), and Novartis International AG
(Switzerland).
Industry News
Dec 2019: Daavlin, a renowned US-based phototherapy units’
manufacturer that utilizes therapeutic UV light to effectively and safely treat
patients with eczema, vitiligo, and psoriasis have joined hands with HealthLens
to give patients better access to receive a dermatology consultation as well as
treatment right from their home. The patient just needs to book a consultation
online, followed by uploading some pictures of the skin condition and brief
health history, after which the information will get electronically encrypted and
sent securely to the physician who will respond within 1-2 days.
No comments:
Post a Comment